Gennova Biopharmaceuticals
Overview
Gennova Biopharmaceuticals, headquartered in Pune, India, is a biotechnology company dedicated to the development, production and commercialization of bio-therapeutics to address life-threatening diseases across various indications. It was established in 2006. We are in the business of transforming healthcare, which we accomplish by manufacturing bio-therapeutics through innovation in bio-manufacturing processes. Since its inception, Gennova has continually focused on innovation in bio-manufacturing processes, as a means to develop safe, efficacious and affordable bio-therapeutics. Incorporating recombinant DNA technologies together with innovative bio-manufacturing practices, Gennova has created a cutting-edge solution for manufacturing and successfully commercializing bio-therapeutics across cardiovascular, neurology, nephrology and oncology markets. Gennova has 7 products in the market ; 5 biosimilar, 1 generic and 1 pioneering – ‘first in the world’ product. Gennova’s Tenectase® is a pioneering work where the first time globally a 3rd generation thrombolytic was approved for arterial ischemic stroke (AIS).
About Us
Gennova Biopharmaceuticals, headquartered in Pune, India, is a biotechnology company dedicated to the development, production and commercialization of bio-therapeutics to address life-threatening diseases across various indications. It was established in 2006. We are in the business of transforming healthcare, which we accomplish by manufacturing bio-therapeutics through innovation in bio-manufacturing processes. Since its inception, Gennova has continually focused on innovation in bio-manufacturing processes, as a means to develop safe, efficacious and affordable bio-therapeutics. Incorporating recombinant DNA technologies together with innovative bio-manufacturing practices, Gennova has created a cutting-edge solution for manufacturing and successfully commercializing bio-therapeutics across cardiovascular, neurology, nephrology and oncology markets. Gennova has 7 products in the market ; 5 biosimilar, 1 generic and 1 pioneering – ‘first in the world’ product. Gennova’s Tenectase® is a pioneering work where the first time globally a 3rd generation thrombolytic was approved for arterial ischemic stroke (AIS).
Headquarters
Pune,Maharashtra